This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
intensive care | 2244 |
stem cell | 1749 |
mean age | 1728 |
mg kg | 1314 |
control group | 1285 |
risk factors | 1270 |
significantly higher | 1257 |
care unit | 1237 |
two groups | 1226 |
one patient | 1146 |
cell transplantation | 1123 |
median age | 1106 |
statistically significant | 1098 |
critically ill | 1091 |
blood donors | 1081 |
years old | 1079 |
bone marrow | 1073 |
mechanical ventilation | 1051 |
significant difference | 1049 |
ng ml | 975 |
septic shock | 958 |
patients received | 944 |
blood pressure | 936 |
blood transfusion | 921 |
university hospital | 876 |
significant differences | 867 |
case report | 866 |
ill patients | 829 |
whole blood | 771 |
mg dl | 765 |
two patients | 762 |
critical care | 755 |
peripheral blood | 733 |
patients admitted | 731 |
red blood | 726 |
design method | 705 |
overall survival | 703 |
patients undergoing | 698 |
high risk | 695 |
retrospective study | 670 |
hematopoietic stem | 670 |
health care | 660 |
study design | 657 |
cardiac arrest | 645 |
emergency department | 632 |
performed using | 627 |
lymph node | 620 |
adverse events | 613 |
hospital stay | 608 |
significantly lower | 601 |
logistic regression | 597 |
present study | 594 |
renal failure | 585 |
mortality rate | 558 |
blood components | 557 |
patients treated | 554 |
pg ml | 551 |
blood products | 534 |
blood donation | 532 |
blood cells | 528 |
statistical analysis | 527 |
study period | 520 |
median time | 517 |
adult patients | 516 |
medical center | 516 |
patients underwent | 515 |
red cell | 510 |
blood samples | 509 |
cd cells | 503 |
apache ii | 502 |
pediatric patients | 501 |
blood group | 500 |
case studies | 498 |
risk factor | 496 |
cystic fibrosis | 495 |
stem cells | 494 |
respiratory failure | 493 |
side effects | 492 |
summary conclusions | 489 |
renal function | 488 |
hospital mortality | 484 |
background case | 481 |
icu admission | 478 |
three patients | 477 |
flow cytometry | 476 |
lymph nodes | 467 |
conditioning regimen | 467 |
blood cell | 466 |
median follow | 465 |
patients without | 462 |
trauma patients | 462 |
ct scan | 461 |
ml min | 458 |
prospective study | 456 |
least one | 455 |
cd cd | 452 |
year old | 451 |
increased risk | 450 |
body weight | 446 |
long term | 444 |
chronic gvhd | 444 |
blood bank | 441 |
multivariate analysis | 440 |
blood loss | 436 |
observational study | 436 |
host disease | 434 |
four patients | 433 |
united states | 432 |
cohort study | 429 |
gene expression | 429 |
acute respiratory | 427 |
patients receiving | 426 |
cardiac surgery | 425 |
free survival | 421 |
icu patients | 418 |
old male | 417 |
minimally invasive | 416 |
regression analysis | 412 |
acute gvhd | 409 |
blood flow | 408 |
ml kg | 406 |
consecutive patients | 406 |
outcome measures | 402 |
significantly increased | 402 |
aft er | 401 |
severe sepsis | 400 |
breast cancer | 400 |
abdominal pain | 397 |
icu stay | 396 |
pet ct | 392 |
organ failure | 392 |
weight loss | 386 |
among patients | 386 |
urinary tract | 380 |
one year | 379 |
results suggest | 378 |
results finding | 375 |
five patients | 369 |
platelet count | 367 |
public health | 365 |
one case | 355 |
included patients | 351 |
metabolic syndrome | 350 |
transfusion medicine | 348 |
significant increase | 347 |
retrospective analysis | 346 |
clinical practice | 345 |
hbv dna | 345 |
body mass | 343 |
cell lines | 341 |
important role | 337 |
inclusion criteria | 336 |
significantly associated | 330 |
care units | 329 |
significantly different | 329 |
main outcome | 327 |
old female | 327 |
epithelial cells | 324 |
year period | 323 |
allogeneic hematopoietic | 323 |
heart rate | 323 |
average age | 322 |
kg day | 320 |
clinical trials | 320 |
infection control | 319 |
pregnant women | 317 |
older adults | 315 |
two cases | 314 |
differential diagnosis | 313 |
mechanically ventilated | 311 |
mass index | 311 |
determine whether | 308 |
medical records | 308 |
red cells | 305 |
computed tomography | 303 |
infectious diseases | 302 |
cell carcinoma | 301 |
patients died | 301 |
blood donor | 300 |
diabetes mellitus | 297 |
complete remission | 297 |
six patients | 296 |
nk cells | 293 |
type diabetes | 291 |
informed consent | 290 |
predictive value | 289 |
replacement therapy | 289 |
protein expression | 288 |
statistical significance | 288 |
gvhd prophylaxis | 286 |
cord blood | 286 |
lung disease | 286 |
age years | 285 |
day mortality | 283 |
respiratory distress | 283 |
brain injury | 281 |
lung injury | 281 |
significantly reduced | 279 |
operative time | 279 |
insulin resistance | 278 |
septic patients | 277 |
analysis showed | 275 |
factors associated | 275 |
laparoscopic surgery | 275 |
measured using | 275 |
tumor cells | 273 |
general hospital | 273 |
last years | 272 |
month period | 272 |
first time | 269 |
data suggest | 268 |
central venous | 266 |
study group | 266 |
nephrotic syndrome | 265 |
chronic hepatitis | 264 |
sofa score | 264 |
soft tissue | 263 |
clinical data | 262 |
per patient | 261 |
prostate cancer | 260 |
old woman | 260 |
patients showed | 260 |
healthy controls | 259 |
seven patients | 259 |
ii score | 256 |
bariatric surgery | 256 |
nervous system | 255 |
patient care | 255 |
study included | 255 |
patients developed | 254 |
please specify | 254 |
patients presented | 254 |
abstract type | 254 |
postoperative complications | 253 |
arterial pressure | 253 |
group i | 252 |
elderly patients | 252 |
significant correlation | 252 |
oxidative stress | 251 |
primary outcome | 251 |
staphylococcus aureus | 250 |
arterial blood | 250 |
total number | 249 |
platelet concentrates | 249 |
healthcare workers | 248 |
iu ml | 248 |
cardiac output | 246 |
transfusion reactions | 246 |
blood glucose | 245 |
serum creatinine | 245 |
within days | 243 |
physical activity | 242 |
cell proliferation | 242 |
gestational age | 242 |
eight patients | 241 |
laparoscopic approach | 241 |
adverse effects | 240 |
kidney injury | 240 |
growth factor | 239 |
clinical trial | 238 |
ethics regulations | 238 |
mg ml | 238 |
sickle cell | 238 |
within hours | 238 |
western blot | 238 |
previous studies | 237 |
study aimed | 236 |
kidney disease | 236 |
clinical outcomes | 235 |
renal disease | 235 |
linear regression | 235 |
clinically significant | 234 |
multiple myeloma | 233 |
th day | 233 |
univariate analysis | 232 |
patients aged | 231 |
inflammatory response | 231 |
retrospective review | 230 |
two years | 229 |
antibiotic therapy | 229 |
high dose | 229 |
smooth muscle | 228 |
higher risk | 227 |
significant reduction | 227 |
mrna expression | 227 |
copies ml | 227 |
heart failure | 227 |
chart review | 226 |
mortality rates | 226 |
physical examination | 225 |
preliminary results | 225 |
small bowel | 225 |
quality control | 224 |
per year | 224 |
gastric cancer | 224 |
graft failure | 223 |
lung cancer | 223 |
cell line | 222 |
clinical course | 222 |
signifi cant | 222 |
old man | 221 |
cell lymphoma | 221 |
lung function | 221 |
coronary artery | 220 |
cancer patients | 220 |
united kingdom | 220 |
analyzed using | 220 |
survival rate | 218 |
muscle mass | 218 |
clinical features | 217 |
three groups | 216 |
renal replacement | 216 |
study showed | 215 |
allogeneic hsct | 215 |
acute kidney | 215 |
prospective observational | 214 |
per day | 214 |
significantly decreased | 214 |
previously reported | 214 |
organ dysfunction | 213 |
colorectal cancer | 213 |
odds ratio | 213 |
significant decrease | 213 |
well tolerated | 212 |
grade iii | 212 |
ventilated patients | 212 |
nine patients | 211 |
time pcr | 211 |
graft versus | 211 |
may lead | 210 |
group ii | 210 |
tidal volume | 210 |
reactive protein | 210 |
allogeneic stem | 210 |
cumulative incidence | 210 |
two different | 210 |
liver disease | 210 |
confidence interval | 210 |
unrelated donor | 209 |
transfusion service | 209 |
left ventricular | 209 |
severe acute | 208 |
pseudomonas aeruginosa | 208 |
surgical treatment | 207 |
age group | 207 |
icu mortality | 206 |
grade ii | 206 |
serum levels | 205 |
blood banks | 204 |
positive correlation | 204 |
cd cell | 204 |
one hundred | 203 |
assessed using | 203 |
myeloid leukemia | 202 |
widely used | 202 |
mean arterial | 202 |
standard deviation | 201 |
months post | 200 |
results showed | 200 |
results indicate | 199 |
hospital discharge | 199 |
patients presenting | 199 |
acute renal | 199 |
patients diagnosed | 199 |
blood supply | 198 |
viral load | 197 |
hospital admission | 197 |
commonly used | 196 |
response rate | 196 |
myocardial infarction | 196 |
regression model | 196 |
endothelial cells | 195 |
nitric oxide | 195 |
single center | 195 |
demographic data | 195 |
family history | 195 |
prognostic factors | 194 |
gold standard | 194 |
cell count | 194 |
analysis revealed | 194 |
versus host | 194 |
early diagnosis | 193 |
pilot study | 193 |
blood cultures | 193 |
results show | 192 |
general population | 192 |
six months | 192 |
medical history | 192 |
acute myeloid | 190 |
pao fio | 190 |
findings suggest | 190 |
retrospective cohort | 189 |
disease progression | 188 |
hospital cardiac | 188 |
surgical procedures | 188 |
randomized controlled | 187 |
birth weight | 187 |
blood units | 186 |
cmv reactivation | 186 |
time points | 186 |
ex vivo | 186 |
blood donations | 186 |
tertiary care | 185 |
postoperative day | 184 |
teaching hospital | 184 |
uric acid | 184 |
family members | 183 |
medical staff | 183 |
real time | 183 |
gastric bypass | 183 |
blood collection | 182 |
patient safety | 182 |
clinical presentation | 182 |
poor prognosis | 182 |
three months | 181 |
clinical characteristics | 181 |
hepatocellular carcinoma | 180 |
retrospectively reviewed | 180 |
rectal cancer | 180 |
systematic review | 179 |
immune system | 179 |
cell disease | 179 |
may also | 179 |
cell transplant | 179 |
recent years | 178 |
blood center | 178 |
patient underwent | 178 |
squamous cell | 177 |
first days | 177 |
patient population | 177 |
traumatic brain | 176 |
independently associated | 176 |
specific ige | 176 |
pulmonary artery | 175 |
months later | 174 |
sectional study | 174 |
blood product | 174 |
blood volume | 173 |
high mortality | 173 |
blood stem | 173 |
related mortality | 173 |
risk patients | 173 |
immune response | 173 |
data collection | 173 |
critical illness | 173 |
myeloablative conditioning | 173 |
first hours | 173 |
medical university | 173 |
medical care | 172 |
nuclear medicine | 171 |
infectious disease | 171 |
one month | 171 |
general surgery | 171 |
normal range | 170 |
clinical outcome | 170 |
oxygen saturation | 170 |
decision making | 169 |
methods materials | 169 |
sample size | 169 |
internal medicine | 169 |
controlled trial | 169 |
respiratory tract | 168 |
heart disease | 168 |
distress syndrome | 168 |
high levels | 168 |
tract infection | 168 |
may contribute | 168 |
respiratory rate | 167 |
study aims | 167 |
high level | 166 |
significant improvement | 166 |
surgical intervention | 166 |
amino acid | 166 |
sleeve gastrectomy | 166 |
data collected | 165 |
exclusion criteria | 165 |
retrospectively analyzed | 165 |
study population | 165 |
even though | 164 |
hernia repair | 164 |
obese patients | 164 |
type i | 164 |
high grade | 164 |
first year | 163 |
renal biopsy | 162 |
adipose tissue | 162 |
days post | 162 |
autologous stem | 161 |
case series | 161 |
male patients | 161 |
pulmonary function | 160 |
poor outcome | 160 |
bile duct | 160 |
patient died | 159 |
primary care | 159 |
multiple organ | 159 |
white blood | 159 |
one week | 159 |
spinal cord | 159 |
significant association | 159 |
saps ii | 159 |
may help | 158 |
overall mortality | 158 |
type ii | 158 |
plasma levels | 157 |
study shows | 157 |
collected data | 157 |
hodgkin lymphoma | 157 |
clinically relevant | 156 |
blood culture | 155 |
disease severity | 155 |
age range | 155 |
positive results | 155 |
patient presented | 154 |
patient received | 154 |
retrospective chart | 153 |
central nervous | 153 |
see table | 153 |
chronic renal | 153 |
postoperative period | 153 |
magnetic resonance | 153 |
acute lymphoblastic | 153 |
ct scans | 153 |
abstract background | 153 |
patients suffering | 153 |
patients required | 153 |
patient developed | 152 |
clinical findings | 152 |
mean time | 152 |
operation time | 152 |
lymphoblastic leukemia | 152 |
states background | 151 |
research abstract | 151 |
chain reaction | 151 |
cardiopulmonary resuscitation | 151 |
medical treatment | 151 |
median number | 151 |
abdominal wall | 150 |
positive cells | 150 |
evaluated using | 150 |
survival rates | 150 |
skeletal muscle | 150 |
high prevalence | 149 |
prospective cohort | 149 |
aged years | 149 |
quality improvement | 149 |
monoclonal antibody | 148 |
blood gas | 148 |
term follow | 148 |
nosocomial infections | 148 |
determined using | 147 |
independent risk | 147 |
fdg pet | 147 |
th ere | 147 |
hcv rna | 146 |
nutritional status | 146 |
two weeks | 146 |
bacterial contamination | 145 |
related complications | 145 |
mononuclear cells | 145 |
surgical patients | 145 |
old girl | 145 |
marrow transplantation | 145 |
may play | 145 |
patient characteristics | 145 |
chest pain | 145 |
polymerase chain | 144 |
square test | 144 |
design methods | 144 |
newly diagnosed | 144 |
clinical symptoms | 144 |
group compared | 144 |
nk cell | 144 |
results findings | 144 |
success rate | 144 |
patients included | 144 |
higher mortality | 143 |
icu discharge | 143 |
trauma center | 143 |
donor chimerism | 143 |
treated patients | 143 |
diagnostic criteria | 143 |
emergency medicine | 142 |
adverse reactions | 142 |
data analysis | 142 |
matched unrelated | 142 |
may result | 142 |
showed significant | 142 |
kg min | 142 |
compared using | 142 |
increased significantly | 142 |
laparoscopic cholecystectomy | 142 |
frozen plasma | 142 |
cell death | 141 |
patients may | 141 |
large number | 141 |
university medical | 141 |
treatment option | 141 |
examination revealed | 141 |
significant changes | 140 |
mean duration | 140 |
chronic kidney | 140 |
median duration | 140 |
reduced intensity | 140 |
acute lung | 140 |
also found | 140 |
airway pressure | 140 |
high incidence | 140 |
scoring system | 139 |
tumor size | 139 |
extremely rare | 139 |
recent studies | 139 |
well known | 139 |
ten patients | 139 |
high frequency | 139 |
nerve conduction | 139 |
low risk | 139 |
cord uid | 138 |
age groups | 138 |
fresh frozen | 138 |
infectious complications | 138 |
doc id | 138 |
remaining patients | 138 |
cardiovascular disease | 138 |
healthy volunteers | 138 |
old boy | 137 |
conditioning regimens | 137 |
cell surface | 137 |
stage renal | 137 |
gastrointestinal tract | 137 |
years ago | 137 |
acute leukemia | 136 |
patients requiring | 136 |
current study | 136 |
renal transplantation | 136 |
year os | 136 |
higher levels | 136 |
monoclonal antibodies | 136 |
rbc units | 136 |
three cases | 135 |
pulmonary disease | 135 |
commercially available | 135 |
mean value | 135 |
term outcomes | 135 |
increased mortality | 135 |
positive patients | 134 |
emergency room | 134 |
female patients | 134 |
diabetic patients | 134 |
mg day | 133 |
pulmonary embolism | 133 |
medical record | 133 |
low dose | 132 |
acute appendicitis | 132 |
tract infections | 132 |
abstract case | 132 |
autologous blood | 132 |
injury severity | 132 |
false positive | 132 |
cd expression | 132 |
report text | 132 |
patient outcomes | 131 |
blood gases | 131 |
higher incidence | 131 |
healthy subjects | 131 |
complete response | 131 |
peripheral neuropathy | 131 |
blood services | 131 |
healthy donors | 131 |
early detection | 131 |
hospitalized patients | 130 |
correlation coefficient | 130 |
rbc transfusion | 130 |
blood safety | 130 |
transfusion services | 129 |
blood component | 129 |
surgical procedure | 129 |
may provide | 129 |
liver function | 129 |
room temperature | 129 |
whole body | 129 |
first case | 129 |
significantly correlated | 129 |
colon cancer | 129 |
female patient | 128 |
intervention group | 128 |
liver cirrhosis | 128 |
vital signs | 128 |
male patient | 128 |
severity score | 128 |
intensity conditioning | 128 |
glomerular filtration | 127 |
wide range | 127 |
electron microscopy | 127 |
selected patients | 127 |
low grade | 127 |
medical students | 126 |
cd ra | 126 |
young adults | 126 |
weight gain | 126 |
conservative treatment | 126 |
results obtained | 126 |
factor viii | 126 |
negative predictive | 126 |
hematopoietic cell | 125 |
health system | 125 |
liver transplantation | 125 |
ejection fraction | 125 |
risk group | 125 |
emergency surgery | 125 |
primary endpoint | 124 |
expression levels | 124 |
may cause | 124 |
three different | 124 |
grade i | 124 |
mean follow | 124 |
platelet transfusion | 124 |
patient age | 123 |
interquartile range | 123 |
mm hg | 123 |
new york | 123 |
transplant recipients | 123 |
public hospitals | 123 |
operating room | 123 |
cardiac index | 123 |
relapse mortality | 122 |
systolic blood | 122 |
viral infections | 122 |
liver biopsy | 122 |
cell source | 122 |
groups according | 121 |
mycophenolate mofetil | 121 |
glucose tolerance | 121 |
disease control | 121 |
function tests | 120 |
medical school | 120 |
descriptive statistics | 120 |
respiratory syndrome | 120 |
nosocomial infection | 120 |
three years | 120 |
infected patients | 120 |
gas exchange | 120 |
hbv infection | 120 |
analysed using | 120 |
antibiotic resistance | 120 |
invasive ventilation | 120 |
common cause | 120 |
pulmonary hypertension | 119 |
gene therapy | 119 |
red cross | 119 |
first line | 119 |
time period | 119 |
prospectively collected | 119 |
significantly improved | 119 |
mouse model | 119 |
bowel obstruction | 118 |
mrna levels | 118 |
copd patients | 118 |
national blood | 118 |
genomic dna | 117 |
calculated using | 117 |
low levels | 117 |
mean number | 117 |
antibiotic treatment | 117 |
grip strength | 117 |
laboratory tests | 117 |
different types | 117 |
wild type | 117 |
partial response | 117 |
lactate levels | 117 |
cardiovascular risk | 116 |
unrelated donors | 116 |
also performed | 116 |
baseline characteristics | 116 |
th percentile | 116 |
peripheral nerve | 116 |
cfu ml | 115 |
treatment options | 115 |
world health | 115 |
donor selection | 115 |
autosomal recessive | 115 |
previously described | 115 |
general anesthesia | 115 |
mental health | 115 |
exome sequencing | 115 |
year follow | 115 |
year overall | 115 |
prognostic factor | 114 |
effective treatment | 114 |
complication rate | 114 |
filtration rate | 114 |
blood transfusions | 114 |
treatment group | 114 |
case reports | 114 |
cell cycle | 114 |
waist circumference | 114 |
renal transplant | 114 |
three days | 114 |
statistical difference | 114 |
future studies | 113 |
clinical pharmacy | 113 |
literature review | 113 |
pressure support | 113 |
physical performance | 113 |
imaging findings | 113 |
ed patients | 113 |
leading cause | 113 |
antibody screening | 113 |
care medicine | 113 |
prospective studies | 113 |
mass spectrometry | 112 |
exact test | 112 |
glasgow coma | 112 |
muscle strength | 112 |
allergic rhinitis | 112 |
antiglobulin test | 112 |
ethics committee | 112 |
surgical resection | 112 |
also significantly | 112 |
month follow | 111 |
investigate whether | 111 |
fdg uptake | 111 |
also observed | 111 |
many patients | 111 |
national health | 111 |
regression models | 111 |
total body | 111 |
robotic surgery | 111 |
head injury | 111 |
animal model | 111 |
body composition | 111 |
within months | 111 |
time point | 110 |
resonance imaging | 110 |
roc curve | 110 |
high rate | 110 |
older people | 110 |
escherichia coli | 110 |
control groups | 110 |
will also | 110 |
acute care | 110 |
hematological malignancies | 109 |
spontaneous breathing | 109 |
one patients | 109 |
invasive surgery | 109 |
learning curve | 109 |
prognostic value | 109 |
preliminary data | 109 |
underwent laparoscopic | 109 |
underlying disease | 109 |
significant impact | 109 |
venous blood | 108 |
nursing staff | 108 |
umbilical cord | 108 |
radical prostatectomy | 108 |
ovarian cancer | 108 |
adverse event | 108 |
rank test | 108 |
protein levels | 108 |
massive transfusion | 108 |
hemolytic anemia | 108 |
blood centers | 107 |
disease status | 107 |
platelet engraftment | 107 |
analysis using | 107 |
neutrophil engraftment | 107 |
combination therapy | 107 |
hiatal hernia | 107 |
acute graft | 107 |
medication reconciliation | 107 |
clinical studies | 107 |
secondary outcomes | 106 |
primary immunodeficiency | 106 |
associated pneumonia | 106 |
resistant staphylococcus | 106 |
plasma samples | 106 |
results demonstrate | 106 |
cognitive impairment | 106 |
five years | 106 |
study conducted | 106 |
trend towards | 105 |
cox regression | 105 |
surgery patients | 105 |
less likely | 105 |
pediatric population | 105 |
bacterial infections | 105 |
negative correlation | 105 |
immune reconstitution | 105 |
early stage | 105 |
electronic medical | 105 |
first months | 105 |
white matter | 105 |
congenital heart | 105 |
immunohistochemical staining | 105 |
small intestine | 105 |
positive samples | 105 |
day post | 104 |
matched sibling | 104 |
platelet counts | 104 |
plasma exchange | 104 |
iron deficiency | 104 |
progressive disease | 104 |
identify patients | 104 |
test results | 104 |
signifi cantly | 104 |
cell dose | 104 |
multivariate logistic | 104 |
patients using | 104 |
skin prick | 104 |
positive predictive | 104 |
term outcome | 104 |
cell types | 103 |
first step | 103 |
hand hygiene | 103 |
stromal cells | 103 |
bladder cancer | 103 |
descriptive abstract | 103 |
small number | 103 |
blood vessels | 103 |
clinical significance | 103 |
studied patients | 103 |
receiver operating | 103 |
blood service | 102 |
genetic testing | 102 |
patients experienced | 102 |
blood groups | 102 |
kidney transplantation | 102 |
specific antibodies | 102 |
short term | 102 |
open surgery | 102 |
may improve | 102 |
data show | 102 |
nucleic acid | 102 |
average time | 102 |
fold increase | 102 |
considered significant | 102 |
done using | 102 |
diagnostic accuracy | 102 |
acute phase | 102 |
weeks gestation | 101 |
liver failure | 101 |
clinical pharmacist | 101 |
may occur | 101 |
patients compared | 101 |
sentinel lymph | 101 |
glucose levels | 101 |
past years | 101 |
three times | 101 |
clinical examination | 101 |
patient demographics | 101 |
patient group | 101 |
clinical signs | 100 |
creatinine clearance | 100 |
first day | 100 |
drug interactions | 100 |
functional outcome | 100 |
aplastic anemia | 100 |
image quality | 100 |
study suggests | 100 |
may represent | 100 |
randomly selected | 99 |
lg ml | 99 |
ards patients | 99 |
clinical response | 99 |
useful tool | 99 |
four cases | 99 |
group received | 99 |
shock patients | 99 |
positive blood | 99 |
multidisciplinary team | 99 |
inguinal hernia | 99 |
information system | 99 |
abdominal surgery | 99 |
chronic inflammatory | 98 |
end stage | 98 |
significantly greater | 98 |
graft function | 98 |
adverse outcomes | 98 |
examination showed | 98 |
randomly assigned | 98 |
inflammatory cytokines | 98 |
blood sample | 98 |
molecular weight | 98 |
node dissection | 98 |
laboratory data | 98 |
generation sequencing | 98 |
fi rst | 98 |
times higher | 98 |
decreased significantly | 97 |
histological examination | 97 |
quality assurance | 97 |
days later | 97 |
also showed | 96 |
died due | 96 |
renal cell | 96 |
differ significantly | 96 |
major cause | 96 |
transplant patients | 96 |
older patients | 96 |
control study | 96 |
bacterial infection | 96 |
patients reported | 96 |
myocardial perfusion | 96 |
well established | 96 |
patients hospitalized | 95 |
hematologic malignancies | 95 |
intravenous immunoglobulin | 95 |
average number | 95 |
transfusion therapy | 95 |
year survival | 95 |
data indicate | 95 |
residual disease | 95 |
second group | 95 |
children aged | 95 |
therapeutic hypothermia | 95 |
western blotting | 95 |
last follow | 95 |
high resolution | 94 |
first group | 94 |
focus group | 94 |
patients years | 94 |
clinical manifestations | 94 |
significantly less | 94 |
lipid profile | 94 |
health organization | 94 |
surgical management | 94 |
transcription factor | 94 |
indocyanine green | 94 |
patients will | 94 |
classified according | 93 |
significant risk | 93 |
solid tumors | 93 |
breast carcinoma | 93 |
icu length | 93 |
laboratory findings | 93 |
per week | 93 |
renal dysfunction | 93 |
one hour | 93 |
metastatic disease | 93 |
retrospective observational | 93 |
routine use | 93 |
plasma membrane | 93 |
paraffin embedded | 93 |
airway epithelial | 93 |
post transplant | 92 |
oxygen delivery | 92 |
food allergy | 92 |
older age | 92 |
endotracheal tube | 92 |
peritoneal dialysis | 92 |
group showed | 92 |
tyrosine kinase | 92 |
sibling donor | 92 |
extracellular matrix | 92 |
hospital length | 92 |
chest wall | 92 |
blot analysis | 92 |
mean values | 92 |
clinical diagnosis | 91 |
first trimester | 91 |
abdominal cavity | 91 |
two days | 91 |
training program | 91 |
protective equipment | 91 |
healthy individuals | 91 |
serum albumin | 91 |
two months | 91 |
class i | 91 |
term survival | 91 |
assess whether | 91 |
surgical technique | 91 |
remains unclear | 91 |
acute pancreatitis | 90 |
serious adverse | 90 |
artery disease | 90 |
epithelial cell | 90 |
thyroid carcinoma | 90 |
community hospitals | 90 |
line treatment | 90 |
transfusion practice | 90 |
study demonstrates | 90 |
four groups | 90 |
small cell | 90 |
fatty acids | 90 |
arterial hypertension | 90 |
situ hybridization | 89 |
emergency medical | 89 |
care patients | 89 |
dose chemotherapy | 89 |
buffy coat | 89 |
group patients | 89 |
predictive factors | 89 |
amino acids | 89 |
renal insufficiency | 89 |
clinical improvement | 89 |
increased expression | 89 |
vascular resistance | 89 |
ed visits | 89 |
patients achieved | 89 |
potential risk | 88 |
patients whose | 88 |
cardiogenic shock | 88 |
surgical icu | 88 |
patients transplanted | 88 |
independent predictor | 88 |
total cholesterol | 88 |
neurological outcome | 88 |
clinical parameters | 88 |
abdominal trauma | 88 |
national university | 88 |
parenteral nutrition | 88 |
healthy children | 88 |
healthcare professionals | 88 |
significant change | 88 |
data regarding | 88 |
radiation dose | 87 |
using two | 87 |
czech republic | 87 |
similar results | 87 |
renal impairment | 87 |
consecutive days | 87 |
antibody screen | 87 |
high quality | 87 |
ml vs | 87 |
negative pressure | 87 |
cell therapy | 87 |
will allow | 87 |
hsct recipients | 86 |
next generation | 86 |
immunosuppressive therapy | 86 |
atrial fibrillation | 86 |
discharged home | 86 |
urinary bladder | 86 |
disease free | 86 |
enrolled patients | 86 |
fio ratio | 86 |
hong kong | 86 |
cell counts | 86 |
developing countries | 86 |
eligible patients | 86 |
venous catheter | 86 |
outcome measure | 86 |
packed red | 86 |
significantly better | 86 |
matched related | 86 |
studies showed | 86 |
health insurance | 86 |
better understand | 86 |
university school | 86 |
pediatric intensive | 86 |
higher rate | 85 |
hemodynamic parameters | 85 |
cmv infection | 85 |
published data | 85 |
younger patients | 85 |
differentially expressed | 85 |
haploidentical donor | 85 |
south africa | 85 |
inflammatory markers | 85 |
stroke volume | 85 |
surface area | 85 |
confidence intervals | 85 |
diffuse large | 85 |
risk assessment | 85 |
autosomal dominant | 84 |
data obtained | 84 |
post operative | 84 |
per month | 84 |
cancer cells | 84 |
female donors | 84 |
controlled trials | 84 |
wistar rats | 84 |
within normal | 84 |
normal saline | 84 |
patient satisfaction | 84 |
descriptive study | 84 |
working group | 84 |
health status | 84 |
important factor | 84 |
anastomotic leak | 84 |
whitney test | 84 |
neuropathic pain | 84 |
stage i | 84 |
broad spectrum | 84 |
main cause | 84 |
radiation exposure | 84 |
connective tissue | 84 |
multicenter study | 84 |
transplanted patients | 84 |
life threatening | 84 |
growth factors | 84 |
line therapy | 84 |
complication rates | 84 |
studies suggest | 84 |
liver injury | 83 |
life support | 83 |
clinical setting | 83 |
emergency departments | 83 |
health services | 83 |
final diagnosis | 83 |
upper gi | 83 |
cd count | 83 |
protective effect | 83 |
way anova | 83 |
female ratio | 83 |
phase i | 83 |
high sensitivity | 83 |
muscle weakness | 83 |
blunt trauma | 83 |
higher rates | 83 |
coronavirus disease | 83 |
last year | 83 |
frequently used | 83 |
ferritin levels | 83 |
respiratory system | 82 |
cardiac function | 82 |
improve patient | 82 |
intracranial pressure | 82 |
induction therapy | 82 |
vast majority | 82 |
serum ferritin | 82 |
biopsy showed | 82 |
false negative | 82 |
gait speed | 82 |
paediatric patients | 82 |
transfusion reaction | 82 |
cells kg | 82 |
investigated whether | 82 |
several studies | 82 |
tertiary hospital | 82 |
gamma camera | 82 |
side effect | 82 |
per unit | 82 |
two methods | 82 |
portal vein | 81 |
postoperative course | 81 |
myelodysplastic syndrome | 81 |
independent predictors | 81 |
urine output | 81 |
fat mass | 81 |
much higher | 81 |
antimicrobial resistance | 81 |
schwann cells | 81 |
clinical information | 81 |
medication adherence | 81 |
relapse rate | 81 |
remained stable | 81 |
immune cells | 81 |
venous pressure | 81 |
flow rate | 81 |
molecular mechanisms | 81 |
healthcare system | 81 |
hiv infection | 81 |
group system | 81 |
pharmaceutical care | 81 |
negative patients | 81 |
first week | 81 |
low level | 81 |
abdominal ct | 80 |
novel coronavirus | 80 |
cd positive | 80 |
surgical site | 80 |
successfully treated | 80 |
severe ards | 80 |
operating characteristic | 80 |
dendritic cells | 80 |
fluid resuscitation | 80 |
personal protective | 80 |
invasive mechanical | 80 |
demographic characteristics | 80 |
higher prevalence | 80 |
fluid balance | 80 |
identified patients | 80 |
right ventricular | 80 |
will provide | 80 |
may affect | 80 |
protein intake | 80 |
chi square | 80 |
time donors | 80 |
time interval | 80 |
relative risk | 80 |
marrow transplant | 80 |
clinical use | 79 |
management system | 79 |
turkey objective | 79 |
serum samples | 79 |
insulin sensitivity | 79 |
recurrence rate | 79 |
mm patients | 79 |
cell carcinomas | 79 |
standard treatment | 79 |
thyroid cancer | 79 |
time spent | 79 |
hip fracture | 79 |
will help | 79 |
single centre | 79 |
fetal growth | 78 |
right side | 78 |
stage iii | 78 |
quantitative pcr | 78 |
coma scale | 78 |
spect ct | 78 |
injured patients | 78 |
metabolic acidosis | 78 |
young patients | 78 |
cross sectional | 78 |
underwent surgery | 78 |
university hospitals | 78 |
chronic obstructive | 78 |
common complication | 78 |
pulmonary edema | 78 |
mean length | 78 |
last months | 77 |
including patients | 77 |
pleural effusion | 77 |
pediatric nephrology | 77 |
health problem | 77 |
fungal infections | 77 |
kidney function | 77 |
grass pollen | 77 |
voluntary blood | 77 |
curative treatment | 77 |
fat diet | 77 |
showed higher | 77 |
surg endosc | 77 |
active disease | 77 |
bronchoalveolar lavage | 77 |
high morbidity | 76 |
conducted using | 76 |
risk stratification | 76 |
donate blood | 76 |
treated cells | 76 |
study will | 76 |
hemorrhagic shock | 76 |
allergic reactions | 76 |
lower extremity | 76 |
continuous infusion | 76 |
total patients | 76 |
positively correlated | 76 |
pts received | 76 |
control subjects | 76 |
animal models | 76 |
aml patients | 76 |
year mortality | 76 |
cell lung | 76 |
i ii | 76 |
iga nephropathy | 76 |
endothelial cell | 76 |
hours post | 76 |
postoperative pain | 76 |
took place | 75 |
data suggests | 75 |
immunohistochemical analysis | 75 |
scan showed | 75 |
gleason score | 75 |
level i | 75 |
prone position | 75 |
identified using | 75 |
patient data | 75 |
national institute | 75 |
case history | 75 |
diff erence | 75 |
grade iv | 75 |
early onset | 75 |
cidp patients | 75 |
may reduce | 75 |
partial remission | 75 |
viral infection | 75 |
major complications | 74 |
general hospitals | 74 |
operative complications | 74 |
poorly understood | 74 |
inflammatory demyelinating | 74 |
node metastasis | 74 |
supportive care | 74 |
colorectal surgery | 74 |
patients suffered | 74 |
hazard ratio | 74 |
table shows | 74 |
matched controls | 74 |
rib fractures | 74 |
safe blood | 74 |
european countries | 74 |
primary objective | 74 |
data showed | 74 |
neoplastic cells | 74 |
without significant | 74 |
sex ratio | 74 |
cardiopulmonary bypass | 74 |
supine position | 74 |
tissue samples | 74 |
using spss | 74 |
patients referred | 73 |
significantly elevated | 73 |
iron overload | 73 |
incidence rate | 73 |
statistically different | 73 |
dependent manner | 73 |
donor screening | 73 |
one third | 73 |
lower limb | 73 |
pulmonary vascular | 73 |
healthy control | 73 |
severity scores | 73 |
mean difference | 73 |
artery bypass | 73 |
plasma glucose | 73 |
least two | 73 |
twelve patients | 73 |
sanger sequencing | 73 |
gram negative | 73 |
chronic pain | 73 |
high fat | 73 |
respiratory symptoms | 73 |
ang ii | 73 |
clinical relevance | 73 |
steroid therapy | 73 |
first study | 73 |
blood banking | 73 |
immunocompromised patients | 73 |
mixed chimerism | 73 |
identifi ed | 73 |
treatment response | 73 |
ob gyn | 73 |
cells showed | 72 |
group consisted | 72 |
membrane oxygenation | 72 |
body temperature | 72 |
hla antibodies | 72 |
patient groups | 72 |
reference laboratory | 72 |
medical college | 72 |
single nucleotide | 72 |
left side | 72 |
eleven patients | 72 |
key role | 72 |
vena cava | 72 |
median cd | 72 |
one day | 72 |
patient outcome | 72 |
daily living | 72 |
antibody identification | 72 |
urine samples | 72 |
case study | 72 |
body fat | 71 |
cell depletion | 71 |
hemolytic transfusion | 71 |
blood count | 71 |
lower respiratory | 71 |
chronic disease | 71 |
marrow failure | 71 |
every patient | 71 |
laboratory parameters | 71 |
significant morbidity | 71 |
positive control | 71 |
direct antiglobulin | 71 |
systemic inflammatory | 71 |
signaling pathway | 71 |
outpatient clinic | 71 |
health outcomes | 71 |
first patient | 71 |
hospital staff | 71 |
brain mri | 70 |
obstructive pulmonary | 70 |
probably due | 70 |
surgical approach | 70 |
chronic graft | 70 |
acute rejection | 70 |
early stages | 70 |
recurrent infections | 70 |
steady state | 70 |
atopic dermatitis | 70 |
good results | 70 |
significant effect | 70 |
chronic inflammation | 70 |
renal tubular | 70 |
disease relapse | 70 |
tested using | 70 |
brain tissue | 70 |
remained unchanged | 70 |
better understanding | 70 |
conversion rate | 70 |
relapsed refractory | 70 |
care facilities | 70 |
innate immune | 70 |
developed acute | 69 |
cell adhesion | 69 |
fluid responsiveness | 69 |
weeks later | 69 |
center study | 69 |
clinical decision | 69 |
light microscopy | 69 |
wound infection | 69 |
fetal dna | 69 |
single institution | 69 |
russian federation | 69 |
needle aspiration | 69 |
significant proportion | 69 |
transitional care | 69 |
crp levels | 69 |
patients met | 69 |
strongly associated | 69 |
carbon dioxide | 69 |
immune responses | 69 |
diastolic blood | 69 |
lower levels | 69 |
patient showed | 69 |
negative bacteria | 69 |
care system | 69 |
folic acid | 69 |
major trauma | 69 |
chronic diseases | 69 |
lower limbs | 69 |
reported cases | 69 |
bone scintigraphy | 69 |
autoimmune diseases | 69 |
drug administration | 68 |
rhd gene | 68 |
urinary protein | 68 |
platelet transfusions | 68 |
mean bmi | 68 |
health workers | 68 |
acute myocardial | 68 |
health professionals | 68 |
disaster preparedness | 68 |
eff ects | 68 |
abstract withdrawn | 68 |
based conditioning | 68 |
vascular endothelial | 68 |
mainly due | 68 |
patients needed | 68 |
mean operative | 68 |
normal controls | 68 |
using standard | 68 |
patients enrolled | 68 |
young children | 68 |
resistant bacteria | 68 |
trauma care | 68 |
following parameters | 68 |
serum level | 68 |
extracorporeal membrane | 68 |
institutional review | 68 |
patients completed | 68 |
clinical impact | 68 |
cases showed | 68 |
foreign body | 68 |
node metastases | 68 |
cell viability | 68 |
days vs | 68 |
copy number | 68 |
limited data | 68 |
pediatric oncology | 67 |
flow cytometric | 67 |
skin lesions | 67 |
abo blood | 67 |
head trauma | 67 |
phase ii | 67 |
systemic inflammation | 67 |
genes involved | 67 |
relatively low | 67 |
estimated blood | 67 |
small sample | 67 |
expression level | 67 |
negative results | 67 |
whole exome | 67 |
hcv infection | 67 |
high doses | 67 |
early postoperative | 67 |
binding protein | 67 |
plasma cells | 67 |
lung tissue | 67 |
clinical evaluation | 67 |
hours later | 67 |
icu admissions | 67 |
alkaline phosphatase | 67 |
significantly shorter | 67 |
kg body | 67 |
progenitor cells | 67 |
haematopoietic stem | 67 |
medical icu | 67 |
fungal infection | 67 |
stage ii | 67 |
intracranial hypertension | 66 |
day survival | 66 |
chronic liver | 66 |
seven days | 66 |
major role | 66 |
community hospital | 66 |
critical role | 66 |
functional status | 66 |
pathogen reduction | 66 |
investigation results | 66 |
urothelial carcinoma | 66 |
rat model | 66 |
potential therapeutic | 66 |
statistical differences | 66 |
within minutes | 66 |
operative day | 66 |
fasting glucose | 66 |
respiratory infections | 66 |
tumor necrosis | 66 |
well documented | 66 |
natural killer | 66 |
young people | 66 |
rare disease | 66 |
wound healing | 66 |
fine needle | 66 |
twice daily | 66 |
invasive approach | 66 |
donor type | 66 |
five cases | 66 |
independent prognostic | 66 |
cell transfusion | 66 |
severe infections | 66 |
nerve injury | 65 |
elective surgery | 65 |
poorly differentiated | 65 |
antigen expression | 65 |
cerebrospinal fluid | 65 |
treatment modality | 65 |
prick tests | 65 |
fatty liver | 65 |
categorical variables | 65 |
early phase | 65 |
glycemic control | 65 |
except one | 65 |
two hundred | 65 |
continuous variables | 65 |
retrospectively evaluated | 65 |
beneficial effect | 65 |
previously published | 65 |
information regarding | 65 |
hb level | 65 |
complete resolution | 65 |
amniotic fluid | 65 |
normal values | 65 |
rare case | 65 |
related donor | 65 |
brain death | 65 |
factors affecting | 65 |
first two | 65 |
imaging studies | 65 |
elevated serum | 65 |
local recurrence | 65 |
ca i | 65 |
mcg kg | 65 |
serum hbv | 65 |
performed according | 65 |
significant higher | 65 |
transplant cyclophosphamide | 64 |
care workers | 64 |
blood mononuclear | 64 |
quality management | 64 |
nerve fibers | 64 |
surge capacity | 64 |
many studies | 64 |
mesenchymal stem | 64 |
physical function | 64 |
background aims | 64 |
review board | 64 |
intermediate care | 64 |
transfused patients | 64 |
research institute | 64 |
severe head | 64 |
primary tumor | 64 |
increasing number | 64 |
higher number | 64 |
beneficial effects | 64 |
additive solution | 64 |
multivariable logistic | 64 |
old patient | 64 |
fold higher | 64 |
solid organ | 64 |
ill children | 64 |
treatment groups | 64 |
skin biopsy | 64 |
regression analyses | 64 |
observational cohort | 64 |
pain management | 64 |
treatment failure | 64 |
diagnostic value | 64 |
second patient | 64 |
serious complications | 64 |
clinical study | 64 |
portal hypertension | 64 |
group iii | 64 |
year post | 64 |
complement activation | 64 |
pathogen inactivation | 64 |
palliative care | 64 |
previously shown | 64 |
adjuvant chemotherapy | 64 |
jugular vein | 63 |
two hours | 63 |
hearing loss | 63 |
blood type | 63 |
bact alert | 63 |
retrospectively analysed | 63 |
corticosteroid therapy | 63 |
salvage therapy | 63 |
died within | 63 |
liver enzymes | 63 |
therapeutic strategies | 63 |
significant relationships | 63 |
may benefit | 63 |
diagnostic tool | 63 |
tissue oxygenation | 63 |
two independent | 63 |
also evaluated | 63 |
control measures | 63 |
care providers | 63 |
conduction studies | 63 |
considered statistically | 63 |
among women | 63 |
past medical | 63 |
maintenance therapy | 63 |
high volume | 63 |
donor lymphocyte | 63 |
muscle cells | 63 |
log copies | 63 |
endotracheal intubation | 63 |
trauma registry | 63 |
evaluate whether | 63 |
tissue sections | 63 |
placebo group | 63 |
oxygen therapy | 63 |
gbs patients | 63 |
controlled study | 63 |
declare background | 63 |
previous study | 63 |
anastomotic leakage | 63 |
elevated levels | 63 |
medical faculty | 63 |
airway management | 63 |
clinical status | 63 |
buffy coats | 63 |
prospective randomized | 63 |
regional blood | 63 |
comparative study | 63 |
monoclonal anti | 63 |
clinical management | 63 |
cell tumors | 62 |
pulmonary fibrosis | 62 |
spindle cells | 62 |
disease activity | 62 |
patient management | 62 |
randomized clinical | 62 |
showed increased | 62 |
class ii | 62 |
least months | 62 |
nutritional support | 62 |
ventilatory support | 62 |
mean score | 62 |
mean apache | 62 |
months follow | 62 |
operating time | 62 |
propensity score | 62 |
patients affected | 62 |
total protein | 62 |
gene mutation | 62 |
first report | 62 |
hemodynamic instability | 62 |
cell activation | 62 |
klebsiella pneumoniae | 62 |
clinical condition | 62 |
biopsy specimens | 62 |
stimulating factor | 62 |
severe complications | 62 |
negative blood | 62 |
immunohistochemical expression | 62 |
study using | 62 |
single dose | 62 |
randomly divided | 62 |
patients also | 62 |
dawley rats | 62 |
total gastrectomy | 62 |
malignant disease | 62 |
preterm birth | 62 |
quantitative analysis | 62 |
prick test | 62 |
imaging modalities | 61 |
long time | 61 |
coronary angiography | 61 |
significantly longer | 61 |
rhce ce | 61 |
mri showed | 61 |
organ damage | 61 |
survival analysis | 61 |
platelet products | 61 |
right hemicolectomy | 61 |
patients submitted | 61 |
chest ct | 61 |
autologous hsct | 61 |
partial nephrectomy | 61 |
study demonstrated | 61 |
transplant related | 61 |
radiation therapy | 61 |
high number | 61 |
paraffin sections | 61 |
admitted patients | 61 |
necrosis factor | 61 |
emergency physicians | 61 |
regional hospital | 61 |
lower risk | 61 |
accurate diagnosis | 61 |
cell depleted | 61 |
plasma concentrations | 61 |
drug resistance | 61 |
pediatric radiology | 61 |
positive rate | 61 |
general practitioners | 61 |
screening tool | 61 |
therapeutic options | 61 |
right upper | 61 |
case presentation | 61 |
ten years | 61 |
laparoscopic sleeve | 60 |
currently available | 60 |
breast carcinomas | 60 |
last two | 60 |
showed significantly | 60 |
failure assessment | 60 |
central hospital | 60 |
major surgery | 60 |
tertiary referral | 60 |
immune deficiency | 60 |
acquired pneumonia | 60 |
observation period | 60 |
poor outcomes | 60 |
rbc transfusions | 60 |
fatty acid | 60 |
study including | 60 |
cox proportional | 60 |
increased levels | 60 |
cytokine production | 60 |
median days | 60 |
full donor | 60 |
different levels | 60 |
cells expressing | 60 |
gastrointestinal stromal | 60 |
clinical history | 60 |
severe thrombocytopenia | 60 |
indirect antiglobulin | 60 |
sentinel node | 60 |
virus infection | 60 |
data support | 60 |
eff ective | 60 |
twenty patients | 60 |
clinical conditions | 60 |
renal injury | 60 |
increased morbidity | 60 |
spindle cell | 60 |
secondary endpoints | 60 |
four years | 60 |
less common | 60 |
clinical suspicion | 60 |
platelet function | 60 |
last decade | 60 |
cant diff | 60 |
prognostic significance | 60 |
cancer cell | 60 |
fasting blood | 59 |
upper gastrointestinal | 59 |
cell culture | 59 |
negative impact | 59 |
hemoglobin level | 59 |
oncology patients | 59 |
reach statistical | 59 |
iv acute | 59 |
right lower | 59 |
pain score | 59 |
electronic health | 59 |
total rna | 59 |
initial diagnosis | 59 |
treatment strategies | 59 |
acute cholecystitis | 59 |
routinely used | 59 |
acute abdomen | 59 |
barr virus | 59 |
outcome data | 59 |
private hospitals | 59 |
also used | 59 |
kg bw | 59 |
reactive oxygen | 59 |
potential role | 59 |
every day | 59 |
intestinal obstruction | 59 |
initial treatment | 59 |
four different | 59 |
inflammatory bowel | 59 |
serum concentrations | 59 |
drug therapy | 59 |
acute physiology | 59 |
odds ratios | 59 |
study evaluated | 59 |
spontaneous circulation | 59 |
also associated | 59 |
complications related | 58 |
may increase | 58 |
international congresses | 58 |
plasma volume | 58 |
one study | 58 |
rich plasma | 58 |
without complications | 58 |
interstitial lung | 58 |
developed countries | 58 |
transfusion safety | 58 |
taken together | 58 |
serious complication | 58 |
neutrophil count | 58 |
cystic duct | 58 |
good clinical | 58 |
bacterial growth | 58 |
patients older | 58 |
proliferative activity | 58 |
open reduction | 58 |
care professionals | 58 |
body irradiation | 58 |
cancer surgery | 58 |
natural history | 58 |
medical education | 58 |
center experience | 58 |
care hospital | 58 |
procedures performed | 58 |
positive cases | 58 |
also increased | 58 |
histopathological examination | 58 |
therapeutic approach | 58 |
kinase inhibitor | 58 |
treatment modalities | 58 |
healthcare providers | 58 |
gel electrophoresis | 58 |
site infection | 58 |
mg daily | 58 |
inflammatory mediators | 58 |
internal fixation | 58 |
least days | 58 |
body surface | 58 |
significant positive | 58 |
inflammatory process | 58 |
risk groups | 58 |
liver resection | 58 |
different time | 58 |
higher proportion | 58 |
nursing home | 58 |
viral hepatitis | 58 |
secondary analysis | 58 |
tolerance test | 58 |
therapeutic option | 58 |
thalassemia major | 58 |
selection criteria | 58 |
low incidence | 57 |
may influence | 57 |
allogeneic hct | 57 |
clear cell | 57 |
ct imaging | 57 |
four months | 57 |
medical sciences | 57 |
early identification | 57 |
analysis demonstrated | 57 |
mean serum | 57 |
transcription factors | 57 |
plasma units | 57 |
streptococcus pneumoniae | 57 |
lymphoma patients | 57 |
blood tests | 57 |
lower incidence | 57 |
hospital setting | 57 |
glucose metabolism | 57 |
storage time | 57 |
retrospective case | 57 |
clinical phenotype | 57 |
times per | 57 |
male female | 57 |
randomized trial | 57 |
performance status | 57 |
apheresis platelets | 57 |
i trauma | 57 |
collected using | 57 |
stable disease | 57 |
good correlation | 57 |
healthcare facilities | 57 |
preliminary study | 57 |
written informed | 57 |
academic medical | 57 |
blood lactate | 57 |
surgical outcomes | 57 |
assessment tool | 57 |
platelet recovery | 57 |
positive impact | 56 |
underwent hsct | 56 |
treated group | 56 |
multivariate analyses | 56 |
donor blood | 56 |
resistance genes | 56 |
patients respectively | 56 |
liver fibrosis | 56 |
severe chronic | 56 |
years later | 56 |
limited number | 56 |
also assessed | 56 |
mean fev | 56 |
non invasive | 56 |
plt count | 56 |
effective method | 56 |
statistical analyses | 56 |
new method | 56 |
public hospital | 56 |
higher level | 56 |
granulomatous disease | 56 |
relatively high | 56 |
platelet aggregation | 56 |
trauma centers | 56 |
multiple trauma | 56 |
recent study | 56 |
six cases | 56 |
therapeutic strategy | 56 |
statistical significant | 56 |
adverse effect | 56 |
important cause | 56 |
minimal residual | 56 |
repeated measures | 56 |
menstrual cycle | 56 |
wilcoxon rank | 56 |
femoral neck | 56 |
oxygen species | 56 |
cirrhotic patients | 56 |
two decades | 56 |
anterior resection | 56 |
international guidelines | 56 |
defi ned | 56 |
autologous hematopoietic | 55 |
mitotic activity | 55 |
antimicrobial therapy | 55 |
converting enzyme | 55 |
drug resistant | 55 |
protein level | 55 |
neurological examination | 55 |
results confirm | 55 |
hiv positive | 55 |
kidney transplant | 55 |
column agglutination | 55 |
subgroup analysis | 55 |
hb levels | 55 |
adverse drug | 55 |
igg levels | 55 |
high blood | 55 |
postmenopausal women | 55 |
every months | 55 |
group vs | 55 |
enteral nutrition | 55 |
premature infants | 55 |
showed high | 55 |
enteral feeding | 55 |
growth restriction | 55 |
emr exchange | 55 |
incisional hernia | 55 |
high rates | 55 |
neonatal intensive | 55 |
oxygen consumption | 55 |
identifi cation | 55 |
microscopic examination | 55 |
blood management | 55 |
preterm delivery | 55 |
second line | 55 |
hypertonic saline | 55 |
immunosuppressive treatment | 55 |
comorbidity index | 55 |
months old | 55 |
per group | 55 |
previous reports | 55 |
carotid artery | 55 |
related problems | 55 |
image analysis | 55 |
segmental glomerulosclerosis | 55 |
patient samples | 55 |
several years | 55 |
developmental delay | 55 |
improved survival | 55 |
among children | 55 |
medical intensive | 55 |
median length | 55 |
tumor cell | 55 |
data will | 55 |
multivariable analysis | 55 |
early post | 55 |
also noted | 55 |
standard deviations | 55 |
vesicoureteral reflux | 55 |
creatinine ratio | 55 |
interstitial fibrosis | 55 |
pain control | 55 |
ischemic stroke | 54 |
steroid treatment | 54 |
invasive fungal | 54 |
immune dysregulation | 54 |
also known | 54 |
care center | 54 |
dna levels | 54 |
complications occurred | 54 |
time course | 54 |
fev predicted | 54 |
median survival | 54 |
two consecutive | 54 |
developed severe | 54 |
muscle actin | 54 |
complete blood | 54 |
research center | 54 |
th week | 54 |
disaster management | 54 |
normal limits | 54 |
cells per | 54 |
also included | 54 |
time consuming | 54 |
lower extremities | 54 |
inhibitory effect | 54 |
oral glucose | 54 |
future research | 54 |
scansystem tm | 54 |
allowed us | 54 |
mortality risk | 54 |
compartment syndrome | 54 |
vein thrombosis | 54 |
emergency care | 54 |
bone metastases | 54 |
axillary lymph | 54 |
may reflect | 54 |
sequential organ | 54 |
hemodynamically stable | 54 |
targeted therapy | 54 |
tumour cells | 54 |
safety profile | 54 |
surgical excision | 54 |
group included | 54 |
trophoblast cells | 54 |
community pharmacy | 54 |
chb patients | 54 |
clinical pharmacists | 54 |
postoperative morbidity | 54 |
ct findings | 54 |
cause mortality | 54 |
new therapeutic | 54 |
physical exam | 54 |
improved significantly | 54 |
first dose | 54 |
node biopsy | 54 |
correct diagnosis | 54 |
treated conservatively | 54 |
transverse colon | 54 |
identical sibling | 53 |
susceptibility testing | 53 |
likert scale | 53 |
will require | 53 |
loading dose | 53 |
five days | 53 |
groups based | 53 |
less frequent | 53 |
lymphocyte count | 53 |
graft survival | 53 |
years post | 53 |
younger age | 53 |
salivary gland | 53 |
bronchial epithelial | 53 |
community pharmacies | 53 |
statistically significantly | 53 |
average length | 53 |
lung transplantation | 53 |
dna samples | 53 |
donor samples | 53 |
allogeneic blood | 53 |
total bilirubin | 53 |
gamma probe | 53 |
clinical case | 53 |
postoperative complication | 53 |
care team | 53 |
increased susceptibility | 53 |
peptic ulcer | 53 |
high percentage | 53 |
within weeks | 53 |
main reason | 53 |
repeat donors | 53 |
tested positive | 53 |
functional outcomes | 53 |
years period | 53 |
hla matched | 53 |
patients infected | 53 |
ct images | 53 |
new zealand | 53 |
general icu | 53 |
many years | 53 |
patients within | 53 |
clostridium difficile | 53 |
cell growth | 53 |
hsct patients | 53 |
progression free | 53 |
gastroesophageal reflux | 53 |
primary immunodeficiencies | 53 |
patients following | 53 |
positive result | 53 |
antiviral therapy | 53 |
platelets stored | 53 |
slightly higher | 53 |
promising results | 53 |
nan title | 53 |
daily dose | 53 |
related quality | 52 |
intermediate risk | 52 |
appropriate treatment | 52 |
differed significantly | 52 |
high degree | 52 |
dna level | 52 |
initial presentation | 52 |
blood system | 52 |
cerebral blood | 52 |
closely related | 52 |
gastric emptying | 52 |
studies will | 52 |
male donors | 52 |
cerebral perfusion | 52 |
cell function | 52 |
common causes | 52 |
term mortality | 52 |
myeloma patients | 52 |
first month | 52 |
survival time | 52 |
severely injured | 52 |
decision support | 52 |
cost effective | 52 |
obtained using | 52 |
patient blood | 52 |
first three | 52 |
vod sos | 52 |
multidisciplinary approach | 52 |
gvhd grade | 52 |
per hour | 52 |
hla class | 52 |
hemorrhagic cystitis | 52 |
data demonstrate | 52 |
scd patients | 52 |
cd ro | 52 |
clinical efficacy | 52 |
mean blood | 52 |
showed similar | 52 |
brain tumors | 52 |
using different | 52 |
significant number | 52 |
without evidence | 52 |
different clinical | 52 |
autoimmune disease | 52 |
study revealed | 52 |
well understood | 52 |
better survival | 52 |
low hb | 52 |
results will | 52 |
normal levels | 52 |
poor response | 52 |
diagnostic laparoscopy | 52 |
iron supplementation | 52 |
marrow biopsy | 52 |
fibrin glue | 52 |
upper respiratory | 52 |
study groups | 52 |
icu los | 52 |
von willebrand | 52 |
lupus erythematosus | 52 |
clinical results | 52 |
missense mutation | 52 |
fully automated | 52 |
abo rh | 52 |
analyzed patients | 52 |
several factors | 52 |
using chi | 51 |
one child | 51 |
bowel disease | 51 |
left ventricle | 51 |
wide variety | 51 |
transfusion transmitted | 51 |
allogeneic sct | 51 |
sixteen patients | 51 |
cell subsets | 51 |
positive dat | 51 |
back pain | 51 |
per kg | 51 |
patients discharged | 51 |
samples collected | 51 |
fangcang shelter | 51 |
significant relationship | 51 |
surgical complications | 51 |
cell differentiation | 51 |
adhesion molecule | 51 |
clinical picture | 51 |
antibiotic prophylaxis | 51 |
still remains | 51 |
well described | 51 |
storage period | 51 |
mast cells | 51 |
internal jugular | 51 |
pulmonary exacerbation | 51 |
plasma concentration | 51 |
childhood cancer | 51 |
fourteen patients | 51 |
renal artery | 51 |
control patients | 51 |
cell concentrates | 51 |
also determined | 51 |
medical equipment | 51 |
endothelial growth | 51 |
combined immunodeficiency | 51 |
also present | 51 |
well defined | 51 |
pediatric patient | 51 |
gastric mucosa | 51 |
biopsy revealed | 51 |
many cases | 51 |
pediatric hematology | 51 |
less invasive | 51 |
inverse correlation | 51 |
cardiac arrests | 51 |
remains controversial | 51 |
maternal plasma | 51 |
trima accel | 51 |
will need | 51 |
strong correlation | 51 |
mass casualty | 51 |
estimated using | 51 |
spectrum antibiotics | 51 |
malignant melanoma | 51 |
higher frequency | 51 |
clinical experience | 51 |
mean hospital | 51 |
usual care | 51 |
occlusive disease | 51 |
autoimmune hemolytic | 51 |
iv antibiotics | 51 |
support ventilation | 51 |
liquid chromatography | 50 |
prophylaxis consisted | 50 |
staff members | 50 |
low molecular | 50 |
will discuss | 50 |
ko mice | 50 |
mr imaging | 50 |
higher percentage | 50 |
improve outcomes | 50 |
depressive symptoms | 50 |
surgical intensive | 50 |
glucose level | 50 |
organ transplantation | 50 |
signaling pathways | 50 |
cell recovery | 50 |
curve analysis | 50 |
internal hernia | 50 |
failure due | 50 |
diff erences | 50 |
identify factors | 50 |
sofa scores | 50 |
undergoing allogeneic | 50 |
within one | 50 |
undergoing elective | 50 |
thrombotic microangiopathy | 50 |
wilms tumor | 50 |
immunohistochemical study | 50 |
donated blood | 50 |
evidence based | 50 |
thirteen patients | 50 |
increasingly used | 50 |
hemolytic disease | 50 |
hospital medical | 50 |
vs days | 50 |
crucial role | 50 |
donor population | 50 |
early recognition | 50 |
house dust | 50 |
second case | 50 |
cervical spine | 50 |
upper quadrant | 50 |
emergency management | 50 |
antibiotic use | 50 |
quantitative real | 50 |
growth retardation | 50 |
ebv reactivation | 50 |
care services | 50 |
hospital transfusion | 50 |
positive effect | 50 |
inferior vena | 50 |
also analyzed | 50 |
eff ect | 50 |
possible role | 50 |
intrauterine growth | 50 |
worse prognosis | 50 |
patient required | 50 |
patient survival | 50 |
blood levels | 50 |
normal renal | 50 |
airway epithelia | 49 |
inflammatory cells | 49 |
resource utilization | 49 |
every hours | 49 |
statistically signifi | 49 |
standard operating | 49 |
graft rejection | 49 |
infection prevention | 49 |
early treatment | 49 |
lower urinary | 49 |
still unclear | 49 |
study performed | 49 |
left upper | 49 |
white cell | 49 |
methods used | 49 |
gi tract | 49 |
ed visit | 49 |
sigmoid colon | 49 |
responding hospitals | 49 |
findings indicate | 49 |
undergoing hsct | 49 |
clinical settings | 49 |
focal segmental | 49 |
randomized study | 49 |
endoplasmic reticulum | 49 |
hospital care | 49 |
pulmonary infection | 49 |
hospital admissions | 49 |
increased incidence | 49 |
late onset | 49 |
time rt | 49 |
liver tissue | 49 |
vascular access | 49 |
medical patients | 49 |
miu ml | 49 |
male gender | 49 |
weeks post | 49 |
severe respiratory | 49 |
type iii | 49 |
induction chemotherapy | 49 |
normal weight | 49 |
frequent complication | 49 |
excluded patients | 49 |
clinical research | 49 |
randomised controlled | 49 |
therapeutic target | 49 |
lupus nephritis | 49 |
related adverse | 49 |
medical centre | 49 |
right ventricle | 49 |
tidal volumes | 49 |
gastrointestinal bleeding | 49 |
superior mesenteric | 49 |
high expression | 49 |
matched healthy | 49 |
known risk | 49 |
center background | 49 |
may explain | 49 |
may require | 49 |
blood centre | 49 |
short time | 49 |
response rates | 49 |
ckd stage | 48 |
large cell | 48 |
also measured | 48 |
significantly related | 48 |
treatment may | 48 |
group antigens | 48 |
artery catheter | 48 |
medical management | 48 |
screening test | 48 |
high throughput | 48 |
multiple linear | 48 |
factors influencing | 48 |
esophageal pressure | 48 |
hoc analysis | 48 |
median os | 48 |
chronic lung | 48 |
available data | 48 |
sos vod | 48 |
rare entity | 48 |
molecular analysis | 48 |
food intake | 48 |
medical services | 48 |
significant increases | 48 |
cost per | 48 |
blood establishments | 48 |
dm patients | 48 |
pulmonary exacerbations | 48 |
tube placement | 48 |
south korea | 48 |
chest compressions | 48 |
morbidly obese | 48 |
collected included | 48 |
cesarean section | 48 |
individual patient | 48 |
standard therapy | 48 |
total score | 48 |
undergoing cardiac | 48 |
good outcome | 48 |
different methods | 48 |
may indicate | 48 |
four weeks | 48 |
burn patients | 48 |
rhd genotyping | 48 |
major risk | 48 |